Biotickr logobiotickr

Madrigal Pharmaceuticals Inc

The MDGL stock trades on Nasdaq All Markets
united states of americatherapeuticssmall-capliver diseasenon-alcoholic steatohepatitis

Company Description

Madrigal is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases. Our most advanced clinical candidate, resmetirom, has the potential to become the first medication approved for the treatment of patients with non-alcoholic steatohepatitis (NASH) with liver fibrosis.

Drug Pipeline

Source: Madrigal Pharmaceuticals Inc - 20220903
Asset
Indication
Phase
resmetirom
Non-Alcoholic Steatohepatitis
Phase 3
 
 
 
 
 

Conversation

0 following
Messages Image
Log in or sign up to join the conversation.
LoginSign up

0 Comments on MDGL stock

Newest

Trialfinder

beta

CompletedDrug Interaction Study of MGL-3196 With Pioglitazone

CompletedDrug Interaction Study of MGL-3196 With Clopidogrel

RecruitingA Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatt...

Relevant Publications

beta

Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease

The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin

Association of Race, Ethnicity, Age and Socioeconomic Status with Access to Virtual Visits within the Brigham & Women's Hospital D...

Antibody and T-Cell Responses to COVID-19 Vaccination in Myeloproliferative Neoplasm Patients

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus...